265 related articles for article (PubMed ID: 9422573)
1. Abdominal irradiation in unilateral nephroblastoma and its impact on local control and survival.
Flentje M; Weirich A; Graf N; Pötter R; Zimmerman H; Ludwig R
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):163-9. PubMed ID: 9422573
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP9/GPOH.
Flentje M; Weirich A; Pötter R; Ludwig R
Radiother Oncol; 1994 Jun; 31(3):222-8. PubMed ID: 8066205
[TBL] [Abstract][Full Text] [Related]
3. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
Tournade MF; Com-Nougué C; de Kraker J; Ludwig R; Rey A; Burgers JM; Sandstedt B; Godzinski J; Carli M; Potter R; Zucker JM;
J Clin Oncol; 2001 Jan; 19(2):488-500. PubMed ID: 11208843
[TBL] [Abstract][Full Text] [Related]
4. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group.
Furtwängler R; Nourkami N; Alkassar M; von Schweinitz D; Schenk JP; Rübe C; Siemer S; Leuschner I; Graf N
Klin Padiatr; 2011 May; 223(3):113-9. PubMed ID: 21509706
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor.
Pachnis A; Pritchard J; Gaze M; Levitt G; Michalski A
Med Pediatr Oncol; 1998 Sep; 31(3):150-2. PubMed ID: 9722896
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.
Breslow NE; Ou SS; Beckwith JB; Haase GM; Kalapurakal JA; Ritchey ML; Shamberger RC; Thomas PR; D'Angio GJ; Green DM
Cancer; 2004 Sep; 101(5):1072-80. PubMed ID: 15329918
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group.
Kalapurakal JA; Li SM; Breslow NE; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; Thomas PR; Grundy P; Green DM; D'Angio GJ
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):201-6. PubMed ID: 19395185
[TBL] [Abstract][Full Text] [Related]
8. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study.
Pritchard J; Imeson J; Barnes J; Cotterill S; Gough D; Marsden HB; Morris-Jones P; Pearson D
J Clin Oncol; 1995 Jan; 13(1):124-33. PubMed ID: 7799012
[TBL] [Abstract][Full Text] [Related]
9. [Preoperative chemotherapy of nephroblastoma. Preliminary results of the SIOP-9/GPO therapy study].
Ludwig R; Weirich A; Pötter R; Harms D; Bürger D; Michaelis J; Erttmann R; Weinel P; Haas RJ; Ritter J
Klin Padiatr; 1992; 204(4):204-13. PubMed ID: 1325574
[TBL] [Abstract][Full Text] [Related]
10. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
11. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor.
Tournade MF; Com-Nougué C; Voûte PA; Lemerle J; de Kraker J; Delemarre JF; Burgers M; Habrand JL; Moorman CG; Bürger D
J Clin Oncol; 1993 Jun; 11(6):1014-23. PubMed ID: 8388918
[TBL] [Abstract][Full Text] [Related]
12. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
[TBL] [Abstract][Full Text] [Related]
13. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
[TBL] [Abstract][Full Text] [Related]
14. [The importance of preoperative chemotherapy and radiotherapy in 373 children with Wilms' tumor].
Gutjahr P; Schwenger M; Spaar HJ; Michaelis J; Niethammer D; Jürgens H; Kühl J; Ludwig R; Kutzner J; Schmidt D
Dtsch Med Wochenschr; 1990 Feb; 115(7):248-53. PubMed ID: 2154366
[TBL] [Abstract][Full Text] [Related]
15. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
Stefanowicz J; Sierota D; Balcerska A; Stoba C
Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
[TBL] [Abstract][Full Text] [Related]
16. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
Irtan S; Jitlal M; Bate J; Powis M; Vujanic G; Kelsey A; Walker J; Mitchell C; Machin D; Pritchard-Jones K;
Eur J Cancer; 2015 Jan; 51(2):225-32. PubMed ID: 25465191
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
Malogolowkin M; Cotton CA; Green DM; Breslow NE; Perlman E; Miser J; Ritchey ML; Thomas PR; Grundy PE; D'Angio GJ; Beckwith JB; Shamberger RC; Haase GM; Donaldson M; Weetman R; Coppes MJ; Shearer P; Coccia P; Kletzel M; Macklis R; Tomlinson G; Huff V; Newbury R; Weeks D;
Pediatr Blood Cancer; 2008 Feb; 50(2):236-41. PubMed ID: 17539021
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry.
Dávila Fajardo R; Oldenburger E; Rübe C; López-Yurda M; Pritchard-Jones K; Bergeron C; Graf N; van Grotel M; van Tinteren H; Saunders D; van den Heuvel-Eibrink MM; Janssens GO; Oldenburger F
Pediatr Blood Cancer; 2018 Aug; 65(8):e27085. PubMed ID: 29693799
[TBL] [Abstract][Full Text] [Related]
20. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
